此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy

2026年8月11日 更新者:H. Lundbeck A/S

Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single- and Multiple-ascending-dose Trial Investigating Safety, Tolerability, and Pharmacokinetics of Lu AH69593 in Healthy Participants, Including Open-label Cohorts to Explore Pharmacodynamic Properties in Participants With Narcolepsy, and Food Effect in Healthy Participants

The purpose of the trial is to determine if Lu AH69593 is safe and well tolerated. The trial will also look at how the body processes Lu AH69593 with and without food.

研究概览

地位

招聘中

研究类型

介入性

注册 (估计的)

104

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Helsinki、芬兰、00380
        • 招聘中
        • Terveystalo Helsinki, Sleep Clinic
      • Turku、芬兰、20520
        • 完全的
        • CRST, Clinical Research Services Turku

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

是的

描述

Key Inclusion Criteria:

For all participants in any trial Part (A, B, C and D):

  • The participant has a resting supine pulse ≥45 and ≤100 beats per minute (bpm) at the Screening Visit and at the Baseline Visit.

Specifically for participants in trial Part A, B, and D:

  • The participant has a body mass index (BMI) ≥18.5 and ≤30 kilograms (kg)/square meter (m^2) at the Screening Visit.
  • The participant has a normal circadian rhythm, defined as a person who usually wakes up between 6:00 and 9:00 a.m. and goes to sleep between 9:00 p.m. and midnight.
  • The participant is ≥18 and ≤55 years of age at the Screening Visit.

Specifically for participants in trial Part C:

  • The participant has a BMI ≥18.5 and ≤35 kg/m^2 at the Screening Visit.
  • The participant has NT1, diagnosed according to International Classification of Sleep Disorders, 3rd edition criteria, with a history of disease diagnosis >3 months prior to the Screening Visit.
  • The participant is ≥18 and ≤64 years of age at the Screening Visit.

Key Exclusion Criteria:

For all participants in any trial Part (A, B, C and D):

  • The participant has previously been enrolled in this trial.
  • The participant has previously been dosed with Lu AH69593.
  • The participant has participated in a clinical trial <30 days prior to the Screening Visit.
  • The participant is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not willing to use adequate contraceptive methods.
  • The participant has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin or adequately treated cervical intraepithelial neoplasia, that has not been in remission for >5 years prior to the first dose of investigational medicinal product (IMP).
  • The participant has worked shifts, including night duty, or has travelled across >3 time zones <2 weeks prior to the first dose of IMP.
  • The participant trains/exercises intensively, for example, for a marathon or triathlon, or at a competitive level.

Specifically for participants in trial Part A, B and D:

  • The participant has had a clinically significant illness from which he/she recovered <4 weeks prior to the first dose of IMP.

Specifically for Participants in trial Part B and C:

  • The participant is at significant risk of suicide based on medical history, mental status, investigator judgement, or the C-SSRS answer of 'yes' to suicidal ideation question 4 or 5 or 'yes' to suicidal behaviour, within the last 6 months on the C-SSRS at the Screening Visit or 'Since last visit' at the Baseline Visit Day -1.

Specifically for participants in trial Part C:

  • The participant has any other disorder for which the treatment takes priority over treatment of narcolepsy or is likely to interfere with trial treatment or impair treatment compliance.
  • The participant has a current medical disorder, other than NT1, associated with excessive daytime sleepiness (EDS).

Note: Other protocol-defined inclusion and exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Part A (Single Ascending Dose [SAD] in Healthy Participants): Lu AH69593 or Placebo
Participants will receive single oral dose of Lu AH69593 or placebo.
安慰剂将按照手臂描述中指定的时间表进行管理。
Lu AH69593 will be administered per schedule specified in the arm description.
实验性的:Part B (Multiple Ascending Dose [MAD] in Healthy Participants): Lu AH69593 or Placebo
Participants will receive Lu AH69593 or placebo orally for 10 days.
安慰剂将按照手臂描述中指定的时间表进行管理。
Lu AH69593 will be administered per schedule specified in the arm description.
实验性的:Part C (MAD in Participants With Narcolepsy Type 1 [NT1]): Lu AH69593
Participants will receive Lu AH69593 orally for 84 days.
Lu AH69593 will be administered per schedule specified in the arm description.
实验性的:Part D (Food Effect in Healthy Participants): Lu AH69593
Participants with receive two single oral doses of Lu AH69593 in fasting or fed condition.
Lu AH69593 will be administered per schedule specified in the arm description.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
大体时间:Baseline up to Day 90
Baseline up to Day 90
Bond Lader Visual Analogue Scale (VAS) dimension scores (Alertness, Contentedness, and Calmness)
大体时间:Baseline up to Day 84
Baseline up to Day 84
Psychomotor Vigilance Task (PVT) Parameter - Change From Baseline in Reaction Time to Stimuli
大体时间:Baseline, up to Day 11
Baseline, up to Day 11
PVT Parameter - Change From Baseline in Number of Errors of Omission
大体时间:Baseline, up to Day 11
Baseline, up to Day 11
PVT Parameter - Change From Baseline in Number of Errors of Commission (Response Without Stimulus)
大体时间:Baseline, up to Day 11
Baseline, up to Day 11
Number of Participants With Suicidal Ideation and Behaviour Based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
大体时间:Baseline up to Day 90
Baseline up to Day 90
Area Under the Curve (AUC) From Zero to Time of Last Quantifiable Concentration (AUC0-t) of Lu AH69593
大体时间:Up to 84 days
Up to 84 days
Maximum Observed Plasma Concentration (Cmax) of Lu AH69593
大体时间:Up to 84 days
Up to 84 days
Time to Reach Cmax (Tmax) of Lu AH69593
大体时间:Up to 84 days
Up to 84 days
AUC From Time Zero to Infinity (AUC0-inf)
大体时间:Up to 6 days
Up to 6 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Email contact via H. Lundbeck A/S、H. Lundbeck A/S

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年6月13日

初级完成 (估计的)

2027年2月9日

研究完成 (估计的)

2027年2月16日

研究注册日期

首次提交

2026年5月15日

首先提交符合 QC 标准的

2026年5月21日

首次发布 (实际的)

2026年5月29日

研究记录更新

最后更新发布 (实际的)

2026年8月12日

上次提交的符合 QC 标准的更新

2026年8月11日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • 20653A
  • 2024-511073-29-00 (克蒂斯)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅